Congenital hypothyroidism
ORPHA:442CategoryAutosomal recessiveAntenatal, Neonatal
Эпидемиология47
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Prevalence at birth | 1-5 / 10 000 | 38 | Europe | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Europe | Class only |
| Prevalence at birth | 1-5 / 10 000 | 10 | France | Value and class |
| Point prevalence | 1-5 / 10 000 | — | France | Class only |
| Prevalence at birth | 6-9 / 10 000 | 57 | United Kingdom | Value and class |
| Point prevalence | 1-5 / 10 000 | — | United Kingdom | Class only |
| Prevalence at birth | 1-5 / 10 000 | 45.5 | Italy | Value and class |
| Prevalence at birth | 6-9 / 10 000 | 57 | Greece | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 55.5 | Cyprus | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 15.5 | Latvia | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Latvia | Class only |
| Prevalence at birth | 1-5 / 10 000 | 49.1 | China | Value and class |
| Point prevalence | 1-5 / 10 000 | — | China | Class only |
| Prevalence at birth | 1-5 / 10 000 | 30.2 | Germany | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Germany | Class only |
| Prevalence at birth | 1-5 / 10 000 | 29.4 | Denmark | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 25 | Poland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Poland | Class only |
| Prevalence at birth | 1-5 / 10 000 | 35 | Estonia | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Estonia | Class only |
| Prevalence at birth | 1-5 / 10 000 | 54.8 | Lebanon | Value and class |
| Prevalence at birth | >1 / 1000 | 150 | Iran, Islamic Republic of | Value and class |
| Prevalence at birth | 6-9 / 10 000 | 73.35 | Brazil | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 43 | Turkey | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Turkey | Class only |
| Prevalence at birth | 1-5 / 10 000 | 35.4 | Australia | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Australia | Class only |
| Prevalence at birth | 6-9 / 10 000 | 63.7 | United Arab Emirates | Value and class |
| Prevalence at birth | 6-9 / 10 000 | 76.9 | Bangladesh | Value and class |
| Prevalence at birth | 6-9 / 10 000 | 62.5 | Pakistan | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 50.2 | Taiwan, Province of China | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 43 | Mexico | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Mexico | Class only |
| Prevalence at birth | 1-5 / 10 000 | 25.3 | Bosnia and Herzegovina | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Bosnia and Herzegovina | Class only |
| Prevalence at birth | 1-5 / 10 000 | 33.7 | Bahrain | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Bahrain | Class only |
| Prevalence at birth | 1-5 / 10 000 | 36 | New Zealand | Value and class |
| Point prevalence | 1-5 / 10 000 | — | New Zealand | Class only |
| Prevalence at birth | 1-5 / 10 000 | 16 | Thailand | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Thailand | Class only |
| Prevalence at birth | 1-5 / 10 000 | — | United States | Class only |
| Point prevalence | 1-5 / 10 000 | 44 | United States | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 37.3 | Specific population | Value and class |
| Annual incidence | 6-9 / 10 000 | 97.0873 | Brazil | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 34.76 | Czech Republic | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 45 | Ireland | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)